Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 14/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058515 | 0.98 | PTGER4 (0.56) | PTGER4CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL10058527 | 0.95 | PTGER4 (0.49) | PTGER4CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL10058525 | 0.94 | PTGER4 (0.48) | PTGER4CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL14431074 | 0.93 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL12002032 | 0.93 | PTGER4 (0.47) | PTGER4CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL13177483 | 0.92 | PTGER4 (0.59) | PTGER4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL14431073 | 0.92 | PTGER4 (0.46) | PTGER4CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL9948014 | 0.89 | PTGER4 (0.66) | PTGER4CYP1A2CYP2D6KDM4E | |
| SCHEMBL13177679 | 0.89 | PTGER4 (0.52) | PTGER4CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL10058509 | 0.89 | PTGER4 (0.53) | PTGER4CYP1A2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-20100069457-A1 | Naphthalene Derivatives Used As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-03-18 | — | — | US | disclosed |
| US-20100069457-A1 | Naphthalene Derivatives Used As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-03-18 | — | — | US | disclosed |
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| WO-2008012344-A1 | NAPHTHALENE DERIVATIVES USED AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012347-A1 | BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007088189-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRK1, OPRD1, OPRL1 | PTGER4 106/4885CYP1A2 41/4885CYP2D6 52/4885 |
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | PTGER4, GPR4, PTGER1 | PTGER4 1/4885CYP1A2 310/4885CYP2D6 393/4885 |
| US-20100069457-A1 | Naphthalene Derivatives Used As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CYP1A2 293/4885CYP2D6 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.